Overview

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if Panobinostat is safe to give to patients and to determine the best dose to give in combination with standard cytarabine and daunorubicin chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Novartis

Treatments:

Cytarabine
Daunorubicin
Histone Deacetylase Inhibitors
Panobinostat